BioVersys AG (SIX: BIOV), a Swiss biopharmaceutical company specializing in treatments for multi-drug resistant (MDR) bacterial infections, will showcase its corporate strategy and pipeline at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York City. This participation underscores the company's ongoing efforts to address the critical global health threat of antimicrobial resistance.
On September 16, 2026, Chief Financial Officer Hernan Levett will deliver a live presentation from 12:30 PM to 1:00 PM ET at the Kennedy II room in the Lotte New York Palace. Additionally, Chief Executive Officer Dr. Marc Gitzinger will provide an on-demand presentation available from September 11, 2026, accessible via the H.C. Wainwright platform or through the BioVersys website in the investor section. The webcast will be available for replay for 90 days, ensuring broad access for investors unable to attend live.
The conference appearance comes at a pivotal time for BioVersys, which is advancing a multi-asset pipeline aimed at overcoming resistance mechanisms in bacteria. Its lead candidate, BV100, is in Phase 3 trials for nosocomial infections caused by Acinetobacter baumannii, a pathogen listed by the World Health Organization as a critical priority for new antibiotics. Another key program, alpibectir, is being developed in collaboration with GlaxoSmithKline (GSK) and a consortium from the University of Lille, France, for tuberculosis and is currently in Phase 2 trials. These programs highlight the company's strategic focus on addressing severe unmet medical needs in both hospital-acquired infections and chronic inflammatory microbiome disorders.
BioVersys leverages two proprietary technology platforms—TRIC and Ansamycin Chemistry—to design candidates that not only overcome existing resistance but also block virulence production, directly targeting the pathogenic mechanisms of harmful bacteria. This dual approach positions the company to offer novel therapeutic options where conventional antibiotics are failing.
The H.C. Wainwright conference provides a key venue for BioVersys to engage with institutional investors, analysts, and potential partners. CEO Dr. Marc Gitzinger and CFO Hernan Levett will be available for one-on-one meetings during the conference, with requests to be coordinated through H.C. Wainwright representatives. The company's participation signals its commitment to advancing its pipeline and securing the necessary resources to bring these critical treatments to market.
With antimicrobial resistance causing an estimated 1.27 million direct deaths in 2019 alone, the need for novel antibacterial therapies is urgent. BioVersys' progress in clinical trials represents a glimmer of hope in an arena where few new antibiotics have been developed in recent decades. By presenting at a major investment conference, BioVersys aims to attract the attention and funding required to accelerate its research and potentially save lives worldwide.
